Symbols / BMRA
BMRA Chart
About
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications, as well as to measure the levels of specific bacteria, hormones, antibodies, antigens, and other substances which may exist in the human body, stools, or blood in extremely small concentrations. It sells its products for treating gastrointestinal diseases and food intolerances, as well as various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also involved in the development of InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and hp+detect, a H. Pylori diagnostic test that indicates if a patient is infected with the Helicobacter pylori bacteria. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 6.22M |
| Enterprise Value | 4.08M | Income | -4.03M | Sales | 4.46M |
| Book/sh | 1.50 | Cash/sh | 0.84 | Dividend Yield | — |
| Payout | 0.00% | Employees | 53 | IPO | — |
| P/E | — | Forward P/E | 5.28 | PEG | — |
| P/S | 1.40 | P/B | 1.37 | P/C | — |
| EV/EBITDA | -0.79 | EV/Sales | 0.92 | Quick Ratio | 2.18 |
| Current Ratio | 3.25 | Debt/Eq | 6.40 | LT Debt/Eq | — |
| EPS (ttm) | -2.51 | EPS next Y | 0.39 | EPS Growth | — |
| Revenue Growth | -26.00% | Earnings | 2023-04-14 16:00 | ROA | -49.44% |
| ROE | -84.30% | ROIC | — | Gross Margin | 5.63% |
| Oper. Margin | -113.47% | Profit Margin | -90.31% | Shs Outstand | 3.02M |
| Shs Float | 2.70M | Short Float | 2.78% | Short Ratio | 2.87 |
| Short Interest | — | 52W High | 6.80 | 52W Low | 2.02 |
| Beta | 0.20 | Avg Volume | 61.27K | Volume | 9.65K |
| Target Price | — | Recom | None | Prev Close | $2.10 |
| Price | $2.06 | Change | -1.92% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$2.06
Latest analyst target
3. DCF / Fair value
$-10.14
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.06
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2020-10-19 | main | Aegis Capital | — → Buy | $11 |
| 2020-09-04 | main | Aegis Capital | — → Buy | $13 |
| 2020-08-21 | init | Aegis Capital | — → Buy | $10 |
| 2018-12-17 | main | B. Riley Securities | Buy → Buy | $6 |
- At-home colon cancer test EZ Detect cleared for nationwide use in Vietnam - Stock Titan Wed, 18 Feb 2026 13
- Biomerica Expands CDMO Services to Meet Rising Demand from Biotechnology and Diagnostic Companies - Quiver Quantitative hu, 06 Nov 2025 08
- Biomerica, Inc. Announces 1-for-8 Reverse Stock Split Effective April 21, 2025 - Nasdaq Wed, 16 Apr 2025 07
- 59.6% of treated patients hit FDA abdominal pain endpoint; Biomerica, Henry Schein to market inFoods® in U.S. (ex NY) - Stock Titan hu, 16 Oct 2025 07
- Biomerica’s Unexpected Surge: Will It Hold Steady? - StocksToTrade hu, 14 Aug 2025 07
- Is BMRA stock positioned well for digital economy - Weekly Risk Summary & Low Volatility Stock Suggestions - mfd.ru Fri, 13 Feb 2026 00
- Gary Huff Joins Biomerica Board as Independent Director — Former LabCorp Diagnostics CEO to Advise Growth - Stock Titan Wed, 08 Oct 2025 07
- Is Biomerica (NASDAQ:BMRA) In A Good Position To Deliver On Growth Plans? - Yahoo Finance Wed, 20 Dec 2023 08
- Biomerica stock plunges to 52-week low of $0.28 - Investing.com Fri, 02 Aug 2024 07
- Is BMRA forming bullish engulfing patterns - Trend Reversal & Weekly Watchlist for Hot Stocks - mfd.ru Wed, 11 Feb 2026 16
- Medicare sets $300 price for new food-trigger test to ease IBS pain - Stock Titan ue, 23 Dec 2025 08
- BMRA Stock Price and Chart — NASDAQ:BMRA - TradingView Mon, 31 Jul 2017 07
- Biomerica (BMRA) - Zacks Investment Research Sat, 23 Apr 2016 05
- Biomerica, Inc. Reports 4% Decline in Operating Expenses Year-to-Date and Strengthens Balance Sheet with 14.7% Improvement in Working Capital - Quiver Quantitative Wed, 14 Jan 2026 08
- Biomerica stock soars after Medicare sets $300 payment rate for IBS test - Investing.com ue, 23 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 52500 | — | — | Stock Award(Grant) at price 0.00 per share. | IRANI ZACKARY S | Chief Executive Officer | — | 2025-12-12 00:00:00 | D |
| 1 | 30000 | — | — | Stock Award(Grant) at price 0.00 per share. | BARBIERI ALLEN | Officer and Director | — | 2025-12-12 00:00:00 | D |
| 2 | 20000 | — | — | Stock Award(Grant) at price 0.00 per share. | MOATAZEDI DAVID | Director | — | 2025-12-12 00:00:00 | D |
| 3 | 20000 | — | — | Stock Award(Grant) at price 0.00 per share. | HUFF GARY M | Director | — | 2025-12-12 00:00:00 | D |
| 4 | 22500 | — | — | Stock Award(Grant) at price 0.00 per share. | CHIN ERIC | Director | — | 2025-12-12 00:00:00 | D |
| 5 | 40000 | — | — | Stock Award(Grant) at price 0.00 per share. | LU GARY | Chief Financial Officer | — | 2025-12-12 00:00:00 | D |
| 6 | 250000 | 77500 | — | Stock Award(Grant) at price 0.31 per share. | IRANI ZACKARY S | Chief Executive Officer | — | 2024-12-13 00:00:00 | D |
| 7 | 110000 | 34100 | — | Stock Award(Grant) at price 0.31 per share. | BARBIERI ALLEN | Officer and Director | — | 2024-12-13 00:00:00 | D |
| 8 | 85000 | 26350 | — | Stock Award(Grant) at price 0.31 per share. | EMERSON JANE | Director | — | 2024-12-13 00:00:00 | D |
| 9 | 85000 | 26350 | — | Stock Award(Grant) at price 0.31 per share. | MOATAZEDI DAVID | Director | — | 2024-12-13 00:00:00 | D |
Financials
| Line Item | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.21 |
| NormalizedEBITDA | -4.74M | -5.99M | -6.87M | -3.94M |
| TotalUnusualItems | 66.86K | |||
| TotalUnusualItemsExcludingGoodwill | 66.86K | |||
| NetIncomeFromContinuingOperationNetMinorityInterest | -4.97M | -5.98M | -7.14M | -4.53M |
| ReconciledDepreciation | 400.00K | 374.00K | 351.00K | 595.00K |
| ReconciledCostOfRevenue | 4.81M | 4.80M | 4.89M | 15.89M |
| EBITDA | -4.74M | -5.99M | -6.87M | -3.94M |
| EBIT | -5.14M | -6.37M | -7.22M | -4.53M |
| NetInterestIncome | 165.00K | 431.00K | 133.00K | 27.00K |
| InterestExpense | 0.00 | 367.00 | ||
| InterestIncome | 165.00K | 431.00K | 133.00K | 27.00K |
| NormalizedIncome | -4.97M | -5.98M | -7.14M | -4.53M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -4.97M | -5.98M | -7.14M | -4.53M |
| TotalExpenses | 10.45M | 11.78M | 12.56M | 23.41M |
| TotalOperatingIncomeAsReported | -5.14M | -6.37M | -7.22M | -4.53M |
| DilutedAverageShares | 2.30M | 2.10M | 1.77M | 1.58M |
| BasicAverageShares | 2.30M | 2.10M | 1.77M | 1.58M |
| DilutedEPS | -2.16 | -2.84 | -4.00 | -2.88 |
| BasicEPS | -2.16 | -2.84 | -4.00 | -2.88 |
| DilutedNIAvailtoComStockholders | -4.97M | -5.98M | -7.14M | -4.53M |
| NetIncomeCommonStockholders | -4.97M | -5.98M | -7.14M | -4.53M |
| NetIncome | -4.97M | -5.98M | -7.14M | -4.53M |
| NetIncomeIncludingNoncontrollingInterests | -4.97M | -5.98M | -7.14M | -4.53M |
| NetIncomeContinuousOperations | -4.97M | -5.98M | -7.14M | -4.53M |
| TaxProvision | 1.00K | 42.00K | 51.00K | 24.00K |
| PretaxIncome | -4.97M | -5.94M | -7.09M | -4.51M |
| OtherIncomeExpense | 1.00K | 66.86K | ||
| OtherNonOperatingIncomeExpenses | 1.00K | |||
| GainOnSaleOfSecurity | 66.86K | |||
| NetNonOperatingInterestIncomeExpense | 165.00K | 431.00K | 133.00K | 27.00K |
| InterestExpenseNonOperating | 0.00 | 367.00 | ||
| InterestIncomeNonOperating | 165.00K | 431.00K | 133.00K | 27.00K |
| OperatingIncome | -5.14M | -6.37M | -7.22M | -4.53M |
| OperatingExpense | 5.63M | 6.98M | 7.67M | 7.51M |
| ResearchAndDevelopment | 1.02M | 1.49M | 1.58M | 1.81M |
| SellingGeneralAndAdministration | 4.61M | 5.49M | 6.08M | 5.70M |
| GrossProfit | 498.00K | 611.00K | 446.00K | 2.98M |
| CostOfRevenue | 4.81M | 4.80M | 4.89M | 15.89M |
| TotalRevenue | 5.31M | 5.42M | 5.34M | 18.87M |
| OperatingRevenue | 5.31M | 5.42M | 5.34M | 18.87M |
| Line Item | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 2.55M | 2.10M | 2.10M | 1.61M |
| ShareIssued | 2.55M | 2.10M | 2.10M | 1.61M |
| TotalDebt | 458.00K | 785.00K | 1.08M | 1.38M |
| TangibleBookValue | 3.88M | 6.38M | 11.56M | 8.15M |
| InvestedCapital | 4.11M | 6.59M | 11.72M | 8.32M |
| WorkingCapital | 3.13M | 5.53M | 10.85M | 7.42M |
| NetTangibleAssets | 3.88M | 6.38M | 11.56M | 8.15M |
| CapitalLeaseObligations | 458.00K | 785.00K | 1.08M | 1.38M |
| CommonStockEquity | 4.11M | 6.59M | 11.72M | 8.32M |
| TotalCapitalization | 4.11M | 6.59M | 11.72M | 8.32M |
| TotalEquityGrossMinorityInterest | 4.11M | 6.59M | 11.72M | 8.32M |
| StockholdersEquity | 4.11M | 6.59M | 11.72M | 8.32M |
| GainsLossesNotAffectingRetainedEarnings | -105.00K | -102.00K | -110.00K | -74.00K |
| OtherEquityAdjustments | -105.00K | -102.00K | -110.00K | -74.00K |
| RetainedEarnings | -53.17M | -48.20M | -42.22M | -35.08M |
| AdditionalPaidInCapital | 57.17M | 54.72M | 52.70M | 42.45M |
| CapitalStock | 203.00K | 168.00K | 1.35M | 1.03M |
| CommonStock | 203.00K | 168.00K | 1.35M | 1.03M |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 1.84M | 2.66M | 2.73M | 3.05M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 100.00K | 459.00K | 785.00K | 1.04M |
| LongTermDebtAndCapitalLeaseObligation | 100.00K | 459.00K | 785.00K | 1.04M |
| LongTermCapitalLeaseObligation | 100.00K | 459.00K | 785.00K | 1.04M |
| CurrentLiabilities | 1.74M | 2.20M | 1.95M | 2.01M |
| OtherCurrentLiabilities | 372.00 | 380.00 | ||
| CurrentDeferredLiabilities | 55.00K | 85.00K | 60.00K | 51.00K |
| CurrentDeferredRevenue | 55.00K | 85.00K | 60.00K | 51.00K |
| CurrentDebtAndCapitalLeaseObligation | 358.00K | 326.00K | 297.00K | 341.00K |
| CurrentCapitalLeaseObligation | 358.00K | 326.00K | 297.00K | 341.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 655.00K | 655.00K | 696.00K | 647.00K |
| PayablesAndAccruedExpenses | 672.00K | 1.14M | 892.00K | 972.00K |
| CurrentAccruedExpenses | 377.00K | 578.00K | 548.00K | 236.00K |
| Payables | 295.00K | 560.00K | 344.00K | 736.00K |
| AccountsPayable | 295.00K | 560.00K | 344.00K | 736.00K |
| TotalAssets | 5.95M | 9.25M | 14.45M | 11.37M |
| TotalNonCurrentAssets | 1.07M | 1.52M | 1.66M | 1.95M |
| OtherNonCurrentAssets | 113.00K | 203.00K | 79.00K | 96.00K |
| InvestmentsAndAdvances | 165.00K | 165.00K | 165.00K | 165.00K |
| InvestmentinFinancialAssets | 165.00K | 165.00K | 165.00K | 165.00K |
| GoodwillAndOtherIntangibleAssets | 228.00K | 212.00K | 165.00K | 170.00K |
| OtherIntangibleAssets | 228.00K | 212.00K | 165.00K | 170.00K |
| NetPPE | 564.00K | 943.00K | 1.25M | 1.52M |
| AccumulatedDepreciation | -2.68M | -2.30M | -1.95M | -2.03M |
| GrossPPE | 3.25M | 3.25M | 3.20M | 3.55M |
| OtherProperties | 3.04M | 3.04M | 2.98M | 3.32M |
| MachineryFurnitureEquipment | 211.00K | 211.00K | 211.00K | 227.00K |
| CurrentAssets | 4.88M | 7.73M | 12.80M | 9.43M |
| OtherCurrentAssets | 255.00K | 238.00K | 300.00K | 320.00K |
| PrepaidAssets | 238.00K | 300.00K | 320.28K | 370.29K |
| Inventory | 1.49M | 2.38M | 2.06M | 2.42M |
| InventoriesAdjustmentsAllowances | -471.00K | -467.00K | -672.00K | -846.00K |
| FinishedGoods | 147.00K | 179.00K | 182.00K | 782.00K |
| WorkInProcess | 743.00K | 1.15M | 869.00K | 763.00K |
| RawMaterials | 1.07M | 1.52M | 1.68M | 1.72M |
| Receivables | 731.00K | 947.00K | 722.00K | 774.00K |
| AccountsReceivable | 731.00K | 947.00K | 722.00K | 774.00K |
| AllowanceForDoubtfulAccountsReceivable | -26.00K | -19.00K | -29.00K | -153.00K |
| GrossAccountsReceivable | 757.00K | 966.00K | 751.00K | 927.00K |
| CashCashEquivalentsAndShortTermInvestments | 2.40M | 4.17M | 9.72M | 5.92M |
| CashAndCashEquivalents | 2.40M | 4.17M | 9.72M | 5.92M |
| Line Item | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 |
|---|---|---|---|---|
| FreeCashFlow | -3.88M | -5.48M | -5.55M | -649.00K |
| RepurchaseOfCapitalStock | 0.00 | -705.00K | -85.00K | -165.92K |
| IssuanceOfCapitalStock | 2.14M | 0.00 | 10.01M | 2.40M |
| CapitalExpenditure | -37.00K | -115.00K | -78.00K | -170.00K |
| InterestPaidSupplementalData | 367.00 | |||
| IncomeTaxPaidSupplementalData | 10.00K | 41.00K | 51.00K | 24.00K |
| EndCashPosition | 2.40M | 4.17M | 9.72M | 5.92M |
| BeginningCashPosition | 4.17M | 9.72M | 5.92M | 4.20M |
| EffectOfExchangeRateChanges | -3.00K | 8.00K | -36.00K | -26.00K |
| ChangesInCash | -1.77M | -5.56M | 3.84M | 1.74M |
| FinancingCashFlow | 2.11M | -81.00K | 9.39M | 2.39M |
| CashFlowFromContinuingFinancingActivities | 2.11M | -81.00K | 9.39M | 2.39M |
| NetOtherFinancingCharges | -47.00K | -81.00K | -705.00K | -85.00K |
| ProceedsFromStockOptionExercised | 15.00K | 0.00 | 81.00K | 77.00K |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 2.14M | 0.00 | 10.01M | 2.40M |
| CommonStockPayments | 0.00 | -705.00K | -85.00K | -165.92K |
| CommonStockIssuance | 2.14M | 0.00 | 10.01M | 2.40M |
| InvestingCashFlow | -37.00K | -115.00K | -78.00K | -170.00K |
| CashFlowFromContinuingInvestingActivities | -37.00K | -115.00K | -78.00K | -170.00K |
| NetIntangiblesPurchaseAndSale | -14.00K | -113.00K | -159.73K | |
| PurchaseOfIntangibles | -14.00K | -113.00K | -159.73K | |
| NetPPEPurchaseAndSale | 0.00 | -51.00K | -64.00K | -57.00K |
| PurchaseOfPPE | 0.00 | -51.00K | -64.00K | -57.00K |
| CapitalExpenditureReported | -37.00K | -64.00K | -14.00K | |
| OperatingCashFlow | -3.84M | -5.36M | -5.47M | -479.00K |
| CashFlowFromContinuingOperatingActivities | -3.84M | -5.36M | -5.47M | -479.00K |
| ChangeInWorkingCapital | 268.00K | -389.00K | 304.00K | 3.60M |
| ChangeInOtherWorkingCapital | -22.00K | 15.00K | 351.00K | 51.00K |
| ChangeInOtherCurrentLiabilities | -327.00K | -297.00K | -297.00K | -244.00K |
| ChangeInOtherCurrentAssets | 8.00K | -44.00K | 18.00K | 169.00K |
| ChangeInPayablesAndAccruedExpense | -465.00K | 205.00K | -31.00K | 647.00K |
| ChangeInAccruedExpense | 1.00K | -41.00K | 49.00K | 258.00K |
| ChangeInPayable | -466.00K | 246.00K | -80.00K | 389.00K |
| ChangeInAccountPayable | -466.00K | 246.00K | -80.00K | 389.00K |
| ChangeInPrepaidAssets | -17.00K | 62.00K | 20.00K | 50.00K |
| ChangeInInventory | 882.00K | -115.00K | 534.00K | 1.56M |
| ChangeInReceivables | 209.00K | -215.00K | -291.00K | 1.36M |
| ChangesInAccountReceivables | 209.00K | -215.00K | -291.00K | 1.36M |
| StockBasedCompensation | 460.00K | 837.00K | 1.19M | 1.26M |
| ProvisionandWriteOffofAssets | 4.00K | -205.00K | -174.00K | -1.46M |
| DepreciationAmortizationDepletion | 400.00K | 374.00K | 351.00K | 595.00K |
| DepreciationAndAmortization | 400.00K | 374.00K | 351.00K | 595.00K |
| Depreciation | 400.00K | 374.00K | 351.00K | 595.00K |
| OperatingGainsLosses | 53.00K | |||
| GainLossOnSaleOfPPE | 0.00 | 53.00K | 0.00 | |
| NetIncomeFromContinuingOperations | -4.97M | -5.98M | -7.14M | -4.53M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for BMRA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|